JP2023518049A5 - - Google Patents
Info
- Publication number
- JP2023518049A5 JP2023518049A5 JP2022555733A JP2022555733A JP2023518049A5 JP 2023518049 A5 JP2023518049 A5 JP 2023518049A5 JP 2022555733 A JP2022555733 A JP 2022555733A JP 2022555733 A JP2022555733 A JP 2022555733A JP 2023518049 A5 JP2023518049 A5 JP 2023518049A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- receptor
- antigen
- protein
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990396P | 2020-03-16 | 2020-03-16 | |
| US62/990,396 | 2020-03-16 | ||
| PCT/US2021/022641 WO2021188599A1 (en) | 2020-03-16 | 2021-03-16 | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518049A JP2023518049A (ja) | 2023-04-27 |
| JP2023518049A5 true JP2023518049A5 (https=) | 2024-06-07 |
Family
ID=77768273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555733A Pending JP2023518049A (ja) | 2020-03-16 | 2021-03-16 | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230212319A1 (https=) |
| EP (2) | EP4592310A2 (https=) |
| JP (1) | JP2023518049A (https=) |
| KR (1) | KR20220169488A (https=) |
| CN (1) | CN116194130A (https=) |
| AU (1) | AU2021237570A1 (https=) |
| BR (1) | BR112022018359A2 (https=) |
| CA (1) | CA3171906A1 (https=) |
| IL (1) | IL296411A (https=) |
| MX (1) | MX2022011417A (https=) |
| WO (1) | WO2021188599A1 (https=) |
| ZA (1) | ZA202210400B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3240805T3 (fi) | 2014-12-15 | 2025-02-17 | Univ California | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori |
| LT3428194T (lt) | 2017-07-14 | 2021-12-10 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| CN113272319A (zh) * | 2018-12-27 | 2021-08-17 | 国立大学法人京都大学 | T细胞受体的变体 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| CN115776991A (zh) * | 2020-05-07 | 2023-03-10 | 华夏英泰（北京）生物技术有限公司 | 改进的t细胞受体-共刺激分子嵌合物 |
| US20230203125A1 (en) * | 2020-05-22 | 2023-06-29 | Chongqing Precision Biotech Co., Ltd. | Fusion protein for reversing tumor microenvironment and use thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN113880953A (zh) * | 2020-07-01 | 2022-01-04 | 华夏英泰（北京）生物技术有限公司 | T细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| US20220089642A1 (en) * | 2020-09-17 | 2022-03-24 | City Of Hope | Fc Receptor-ACE2 Conjugates and Use Thereof |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| WO2023086379A2 (en) * | 2021-11-10 | 2023-05-19 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3239740A1 (en) * | 2021-12-03 | 2023-06-08 | Tim C. LEUTKENS | High selective cd229 antigen binding domains and methods of use |
| AU2022423987A1 (en) * | 2021-12-29 | 2024-07-11 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
| CN118871460A (zh) * | 2022-01-07 | 2024-10-29 | 维硕公司 | 经工程化的PD-L1靶向γδT细胞受体 |
| CA3245762A1 (en) * | 2022-03-25 | 2023-09-28 | Shanghai Henlius Biologics Co., Ltd. | ANTI-MSLN ANTIBODIES AND METHODS OF USE |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN115786272B (zh) * | 2023-01-05 | 2025-02-14 | 厦门大学 | 靶向SARS-Cov-2的TCR-T的制备方法及其应用 |
| WO2024148337A1 (en) * | 2023-01-05 | 2024-07-11 | Angeles Therapeutics, Inc. | Methods and compositions for gene transduction and to control the activity of synthetic and immune receptors |
| WO2024189620A1 (en) * | 2023-03-13 | 2024-09-19 | Canopy Immuno-Therapeutics Ltd. | Ig-like fusion proteins for treating pemphigus vulgaris and foliaceus |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| EP4694900A1 (en) * | 2023-04-13 | 2026-02-18 | The Johns Hopkins University | Engineered t-cell receptors and methods of making and using the same |
| CN117143823B (zh) * | 2023-09-11 | 2024-07-16 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 |
| WO2025213182A1 (en) * | 2024-04-05 | 2025-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Combinatorial approaches for targeting hematopoietic cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| US20260015401A1 (en) * | 2024-07-10 | 2026-01-15 | Angeles Therapeutics, Inc. | Compositions and methods comprising epitopes and polypeptides |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| PT2768942T (pt) | 2011-10-17 | 2020-01-21 | Massachusetts Inst Technology | Entrega intracelular |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| WO2015069922A2 (en) * | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| BR112016018100A2 (pt) | 2014-02-07 | 2018-02-20 | Univ Mcmaster | acoplador antigênico de células t trifuncional, métodos e usos do mesmo |
| EP3209699A1 (en) | 2014-10-22 | 2017-08-30 | Crescendo Biologics Limited | Vh scaffold |
| DK3209698T4 (da) | 2014-10-22 | 2022-04-04 | Crescendo Biologics Ltd | Transgene mus |
| GB201500463D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| GB201500464D0 (en) | 2015-01-12 | 2015-02-25 | Crescendo Biolog Ltd | Method of producing optimised therapeutic molecules |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| DE102015101304B3 (de) | 2015-01-29 | 2016-03-17 | Fujitsu Technology Solutions Intellectual Property Gmbh | Rackserver für ein Serverrack |
| US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
| US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| WO2016168769A1 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| KR20180075689A (ko) | 2015-11-23 | 2018-07-04 | 트르스티스 오브 보스톤 유니버시티 | 키메라 항원 수용체에 관한 방법 및 조성물 |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| EP3529268B1 (en) | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| JP7291396B2 (ja) * | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| EP3548055A4 (en) * | 2016-12-02 | 2020-08-19 | University of Southern California | SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| US20190359678A1 (en) * | 2017-02-09 | 2019-11-28 | The Regents Of The University Of California | Chimeric t cell antigen receptors and methods of use thereof |
| CN106939048A (zh) * | 2017-03-25 | 2017-07-11 | 康众（北京）生物科技有限公司 | 一种CD3ε×CD19双特异性纳米抗体及其制备方法 |
| JP7538601B2 (ja) * | 2017-04-26 | 2024-08-22 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| ES2928296T3 (es) | 2017-06-30 | 2022-11-16 | Us Health | Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos |
| EP3681908A1 (en) | 2017-09-13 | 2020-07-22 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| WO2019067805A1 (en) | 2017-09-27 | 2019-04-04 | University Of Southern California | NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY |
| KR20250070609A (ko) | 2017-11-14 | 2025-05-20 | 아르셀엑스, 인크. | 다기능성 면역 세포 요법 |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| EP3746470A1 (en) | 2018-01-31 | 2020-12-09 | F. Hoffmann-La Roche AG | Stabilized immunoglobulin domains |
| JOP20200234A1 (ar) | 2018-03-27 | 2020-09-15 | Xyphos Biosciences Inc | نطاقات a1-a2 معدلة لمركبات ترابطية nkg2d غير طبيعية ترتبط بمستقبلات nkg2d غير طبيعية. |
| JP7599205B2 (ja) | 2018-06-01 | 2024-12-13 | アンヘレス セラピューティクス インコーポレイテッド | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| CN112566643A (zh) * | 2018-06-12 | 2021-03-26 | 加利福尼亚大学董事会 | 用于治疗癌症的单链双特异性嵌合抗原受体 |
| BR112020024074A2 (pt) * | 2018-07-20 | 2021-02-17 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd19 |
| JP7641223B2 (ja) | 2019-01-28 | 2025-03-06 | サイフォス、バイオサイエンシズ、インコーポレイテッド | Ｃａｒ細胞上の非天然ｎｋｇ２ｄ受容体に、結合した異種分子を選択的に送達する改変非天然ｎｋｇ２ｄリガンド |
-
2021
- 2021-03-16 CA CA3171906A patent/CA3171906A1/en active Pending
- 2021-03-16 IL IL296411A patent/IL296411A/en unknown
- 2021-03-16 JP JP2022555733A patent/JP2023518049A/ja active Pending
- 2021-03-16 EP EP25170593.5A patent/EP4592310A2/en active Pending
- 2021-03-16 US US17/912,423 patent/US20230212319A1/en active Pending
- 2021-03-16 KR KR1020227034277A patent/KR20220169488A/ko active Pending
- 2021-03-16 AU AU2021237570A patent/AU2021237570A1/en active Pending
- 2021-03-16 BR BR112022018359A patent/BR112022018359A2/pt unknown
- 2021-03-16 EP EP21771595.2A patent/EP4121079A4/en not_active Withdrawn
- 2021-03-16 MX MX2022011417A patent/MX2022011417A/es unknown
- 2021-03-16 WO PCT/US2021/022641 patent/WO2021188599A1/en not_active Ceased
- 2021-03-16 CN CN202180021646.6A patent/CN116194130A/zh active Pending
-
2022
- 2022-09-20 ZA ZA2022/10400A patent/ZA202210400B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518049A5 (https=) | ||
| JP2021525509A5 (https=) | ||
| IL273201B1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
| JP2024518011A5 (https=) | ||
| JP2021500861A5 (https=) | ||
| JP2020500530A5 (https=) | ||
| JP2024059628A (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| JP2023525720A5 (https=) | ||
| DK2614077T3 (en) | Chimeric antigen receptors with an optimized hinge region | |
| JP2025037871A5 (https=) | ||
| US20230028399A1 (en) | Bcma-directed cellular immunotherapy compositions and methods | |
| JP2024518011A (ja) | 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 | |
| IL297514A (en) | Vectors and methods for in vivo transduction | |
| JP2023518049A (ja) | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 | |
| JP2019518424A5 (https=) | ||
| JP2020517263A5 (https=) | ||
| US20230390392A1 (en) | Multiplex gene edited cells for cd70-directed cancer immunotherapy | |
| JP2024519335A5 (https=) | ||
| CA3126431A1 (en) | Receptors providing targeted costimulation for adoptive cell therapy | |
| US20210095029A1 (en) | Compositions and methods for treating cancer | |
| AU2021307614A1 (en) | Engineered immune cell for allotransplantation | |
| JP2024510900A5 (https=) | ||
| IL297547A (en) | Therapeutic interventional particles for the corona virus | |
| JP2023548829A5 (https=) | ||
| KR20240033025A (ko) | Bcma-지시된 세포 면역요법 조성물 및 방법 |